[Update] Covid Early Treatment

19 September 2021 — Swiss Policy Research

by Swiss Policy Research

Artemisia annua: In vitro efficacy against SARS-CoV-2 replication (Nair et al.)

In view of non-durable covid vaccine protection, the availability of effective early treatment options for high-risk covid patients remains a top priority.

Based on promising peer-reviewed pre-clinical and early clinical results, SPR has added artemisia annua and arginine to its covid early treatment protocol (see linked studies therein).

Concerning ivermectin, several positive studies turned out to be fraudulent or unreliable; if all low-quality studies are excluded, the benefit of ivermectin is no longer statistically significant. Some beneficial immuno-modulatory effect – as found by the French Institute Pasteur – is still plausible, but the available evidence has become rather uncertain.

The SPR Covid Early Treatment Protocol is available in English and in German.

As always, patients are asked to consult a doctor.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.